- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Vinva Investment Management Ltd Lowers Holdings in Biogen Inc.
Biotechnology firm Biogen sees institutional investor decrease stake by over 34%
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
Vinva Investment Management Ltd, an institutional investor, decreased its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 34.2% in the 3rd quarter, according to the company's recent Form 13F filing with the Securities & Exchange Commission. The fund now owns 38,704 shares of the biotechnology company's stock, down from 58,862 shares previously.
Why it matters
Biogen is a major biotechnology firm focused on developing treatments for neurological and neurodegenerative diseases. Changes in institutional ownership can signal shifts in investor sentiment and market expectations around the company's performance and pipeline.
The details
According to the 13F filing, Vinva Investment Management Ltd sold 20,158 shares of Biogen stock during the 3rd quarter. The firm's remaining stake in Biogen is valued at $5,361,000. The sale represents a 34.2% decrease in Vinva's holdings of the biotechnology company's shares.
- Vinva Investment Management Ltd decreased its Biogen holdings in the 3rd quarter of 2026.
The players
Vinva Investment Management Ltd
An institutional investment management firm that has decreased its stake in Biogen Inc. by over 34% in the most recent quarter.
Biogen Inc.
A multinational biotechnology company focused on developing treatments for neurological and neurodegenerative diseases.
The takeaway
The reduction in Vinva Investment Management's Biogen holdings could signal a shift in investor sentiment around the biotechnology company, though further analysis of Biogen's broader institutional ownership and financial performance would be needed to fully assess the implications.
